DFW Capital Partners Named One of Top 50 Private Equity Firms for Executives

For Immediate Release February 10, 2023 Teaneck, NJ   DFW Capital Partners was named as one of the Top 50 Private Equity Firms for Executives – https://www.businesswire.com/news/home/20230208005242/en/PE-CXO-and-Falcon-Recognize-the-Top-50-Private-Equity-Firms-for-Executives The list highlights the funds whose governance style, engagement, and fit are seen as best enabling their executive partners to achieve success. The winners were selected through a… Read more »

DFW Closes Latest Investment Fund at $800 Million Hard Cap

For Immediate Release January 3, 2023 Teaneck, NJ DFW Capital Partners announced today that it has held the final closing of DFW Capital Partners VII, L.P. (“Fund VII”), an investment partnership dedicated to making control investments in lower-middle market service companies. DFW initially sought $750 million in commitments, and was over-subscribed at its hard cap… Read more »

Sebela Pharmaceuticals Announces New Division Named Sebela Women’s Health

Kelly Culwell, MD, Joins as Head of Research and Development, Women’s Health with a Focus on Innovative Products That Meet Women’s Needs ROSWELL, Ga., Nov. 15, 2022 /PRNewswire/ — Sebela Pharmaceuticals® today announced a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the… Read more »

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada   Phase 3 Trials Initiated with Tegoprazan for the Treatment of Erosive Esophagitis and Non-erosive Reflux Disease Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader… Read more »

American Track Services Acquires The Railroad Associates Corp.

Fort Worth, Texas, April 1, 2022.   As the Nation’s leading provider of inspection, maintenance, repair and specialized construction services for industrial railroad infrastructure, American Track is proud to announce the acquisition of The Railroad Associates Corp (TRAC) in Boiling Springs, PA. In 2021 DFW Capital Partners acquired American Track and has assisted with an aggressive… Read more »

DFW Capital Partners promotes Patrick Fairfield to Vice President

For Immediate Release March 31, 2022 Teaneck, NJ DFW Capital Partners announced today that Patrick Fairfield has been promoted to the position of Vice President. Based in the firm’s Teaneck, NJ office, Pat joined DFW in 2017 as an Associate. Pat has been actively involved in deal execution, debt financing arrangement and portfolio monitoring for… Read more »

DFW Capital Partners Exits Children’s Dental Management

For Immediate Release January 12, 2022 Teaneck, NJ DFW Capital Partners successfully exits its investment in Children’s Dental Management DFW Capital Partners (“DFW”) is pleased to announce that it has completed the sale of its portfolio company, CDHA Holdings, LLC (“Children’s Dental Management”, “CDM” or the “Company”). CDM is the largest pediatric specialist-led dental support… Read more »

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

BRIDGEWATER, N.J. & ROSWELL, Ga.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while… Read more »

Saol Announces FDA Approval of LYVISPAHTM and Divesture

December 6, 2021 Saol Therapeutics Announces FDA Approval of LYVISPAHTM (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio Saol Therapeutics announces the approval of LYVISPAHTM (baclofen) oral granules. The company also announces the strategic transaction to divest the plasma-derived hyperimmune portfolio to Kamada Ltd. for a total value of up to $160M… Read more »

DFW Capital Partners Closes Investment in Herspiegel Consulting

December 14, 2021 DFW Capital Partners (“DFW”), announced today that it has completed a growth investment in Herspiegel Consulting, a leading provider of commercial strategy and implementation consulting for the pharmaceutical and biotechnology industry. Founded in 2007 and headquartered in Yardley, PA, Herspiegel Consulting has advised start-ups to Fortune 100 pharmaceutical clients on commercial projects… Read more »